Formulation and Development of Medicated Chewing Gum Containing Ondansetron and Domperidone
DOI:
https://doi.org/10.61554/ijnrph.v1i1.2023.19Abstract
This study aimed to determine the feasibility of combining ondansetron and domperidone into a single medicated gum. Molded Chewing Gum (MCG) was developed via direct compression. Our medicated chewing gum was designed with diabetics in mind, and Stevia was selected for the research because it does not increase blood glucose levels. Direct compression was used in the development of medicated gum. Each formulation's permissible flow characteristics and pre-compression parameters, including bulk density, tapered density, Carr's compressibility index, and Hausner ratio, were shown. After compression, it was determined that all of the parameters were within acceptable limits, including changes in weight, thickness, appearance, and in vitro drug release. There is no indication of drug-excipient interactions based on physical testing or TLC analysis. Two plasticizers only when comparing glycerol with coconut oil, the latter proved to be the superior plasticizer. Formulation F6 was chosen as the best option since all of the attributes fall within the expected range. The results of the F6 formulation were analyzed for their thickness, weight fluctuation, appearance, and in vitro drug release. Coconut oil shown to be the superior plasticizer for making MCG after testing and evaluation. Probably because the concentration is optimized for releasing the drug from the formulation, the fact that F6 includes 24 mg of coconut oil makes it a more effective formulation.
Downloads
Metrics
Keywords:
Chewing Gum, Ondansetron, Domperidone, Direct Compression, Antiemetic.Downloads
Published
How to Cite
Issue
Section
References
Navya M, Rao NM. Chewing gum as a drug delivery system. Int J Pharm Bio Sci. 2014;5:148–61.
Jadhav AV, Mohite SK. A comprehensive review on: Medicated chewing gum. Journal of Current Pharma Research [Internet]. 2014;4(3):1215–24. Available from: http://dx.doi.org/10.33786/jcpr.2014.v04i03.0 06 DOI: https://doi.org/10.33786/JCPR.2014.v04i03.006
Modified- Release Drug Delivery Technology”. New York: Marcel Dekker; 2002.
Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation”. Cochrane Database Syst Rev. 2001;3. DOI: https://doi.org/10.1002/14651858.CD000146
Seppä L, Salmenkivi S, Hausen H. Salivary fluoride concentration in adults after different fluoride procedures. Acta Odontol Scand [Internet]. 1997;55(2):84–7. Available from: http://dx.doi.org/10.3109/0001635909115397 DOI: https://doi.org/10.3109/00016359709115397
Munksgaard EC, Nolte J, Kristensen K. Adherence of chewing gum to dental restorative materials. Am J Dent. 1995;8(3):137–9.
Weil AT. Coca leaf as a therapeutic agent. Am J Drug Alcohol Abuse [Internet]. 1978;5(1):75–86. DOI: https://doi.org/10.3109/00952997809029262
Asija R, Patel S, Asija S. Oral dosages forms: Medicine containing chewing gum: A review. J Drug Delivery Ther. 2012;90–5. DOI: https://doi.org/10.22270/jddt.v2i6.333
Cherukuri SR, Bikkina K. Tableted Chewing gum composition and method of preparation. U.S. Patent; 1988.